Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	**HITIQ Limited**
ACN	**609 543 213**

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michael Dean Vegar
Date of last notice	13 July 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct/Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Michael Dean Vegar <M Vegar Investment A/C> (Mr Vegar is a beneficiary of the Trust)
Date of change	31 March 2022

No. of securities held prior to change	**Indirect** 6,729,166 Fully Paid Ordinary Shares (6,616,167 Escrowed to 16 June 2023) **Direct** 375,000 Fully Paid Ordinary Shares (300,000 Escrowed to 16 June 2023) 500,000 Performance Rights expiring on 31 July 2022 vesting upon contract signing and finalisation of a deal with an Australian national sporting code with minimum audited revenue of $200,000 pa excluding GST by 31 March 2022. 1,500,000 Unlisted Options exercisable at $0.30 on or before 25 March 2024 Vesting upon the Company achieving annual recurring revenue of not less than $2m within two years of date of listing. (Escrowed to 16 June 2023) 3,000,000 Unlisted Options exercisable at $0.30 on or before 25 March 2024 Vesting upon the Company achieving 510k or De Novo Approval from the US Food and Drug Administration for CoVR within 2 years from the date of listing. (Escrowed to 16 June 2023) 1,500,000 Unlisted Options exercisable at $0.30 on or before 25 March 2025 Vesting upon the Company achieving annual recurring revenue of not less than $4m within three years of date of listing. (Escrowed to 16 June 2023)
Class	Performance Rights
Number acquired	-
Number disposed	500,000

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil – Performance Rights Lapsed
No. of securities held after change	**Indirect** 6,729,166 Fully Paid Ordinary Shares (6,616,167 Escrowed to 16 June 2023) **Direct** 375,000 Fully Paid Ordinary Shares (300,000 Escrowed to 16 June 2023) 1,500,000 Unlisted Options exercisable at $0.30 on or before 25 March 2024 Vesting upon the Company achieving annual recurring revenue of not less than $2m within two years of date of listing. (Escrowed to 16 June 2023) 3,000,000 Unlisted Options exercisable at $0.30 on or before 25 March 2024 Vesting upon the Company achieving 510k or De Novo Approval from the US Food and Drug Administration for CoVR within 2 years from the date of listing. (Escrowed to 16 June 2023) 1,500,000 Unlisted Options exercisable at $0.30 on or before 25 March 2025 Vesting upon the Company achieving annual recurring revenue of not less than $4m within three years of date of listing. (Escrowed to 16 June 2023)

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Lapsing of Performance Rights

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.